Business Description
![AIM ImmunoTech Inc AIM ImmunoTech Inc logo](https://static.gurufocus.com/logos/0C00000B9G.png?14)
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US42366C3016
Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.27 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -41.05 | |||||
Beneish M-Score | -8.74 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.2 | |||||
3-Year EBITDA Growth Rate | -16.9 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -9.4 | |||||
3-Year Book Growth Rate | -48.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 6 | |||||
Future 3-5Y Total Revenue Growth Rate | 214.29 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.81 | |||||
9-Day RSI | 40.76 | |||||
14-Day RSI | 43.31 | |||||
6-1 Month Momentum % | -6.82 | |||||
12-1 Month Momentum % | -34.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 1.11 | |||||
Days Sales Outstanding | 1664.25 | |||||
Days Payable | 27611.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | -6.23 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.09 | |||||
Operating Margin % | -17282.9 | |||||
Net Margin % | -16123.32 | |||||
FCF Margin % | -11633.16 | |||||
ROE % | -151.37 | |||||
ROA % | -115.67 | |||||
ROIC % | -596.18 | |||||
ROC (Joel Greenblatt) % | -3221.58 | |||||
ROCE % | -154 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 91.21 | |||||
PB Ratio | 4.56 | |||||
Price-to-Tangible-Book | 9.12 | |||||
EV-to-EBIT | -0.41 | |||||
EV-to-EBITDA | -0.41 | |||||
EV-to-Revenue | 69.75 | |||||
EV-to-Forward-Revenue | 92.83 | |||||
EV-to-FCF | -0.6 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -107.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:AIM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AIM ImmunoTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.193 | ||
EPS (TTM) ($) | -0.64 | ||
Beta | 1.19 | ||
Volatility % | 37.27 | ||
14-Day RSI | 43.31 | ||
14-Day ATR ($) | 0.032154 | ||
20-Day SMA ($) | 0.375305 | ||
12-1 Month Momentum % | -34.48 | ||
52-Week Range ($) | 0.3054 - 0.7222 | ||
Shares Outstanding (Mil) | 57.14 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
AIM ImmunoTech Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
AIM ImmunoTech Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
AIM ImmunoTech Inc Frequently Asked Questions
What is AIM ImmunoTech Inc(AIM)'s stock price today?
The current price of AIM is $0.36. The 52 week high of AIM is $0.72 and 52 week low is $0.31.
When is next earnings date of AIM ImmunoTech Inc(AIM)?
The next earnings date of AIM ImmunoTech Inc(AIM) is 2024-08-15 Est..
Does AIM ImmunoTech Inc(AIM) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIM) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |